Novel immunotherapies for adult patients with B-lineage acute lymphoblastic leukemia

The past decade witnessed the rapid development of adult B-lineage acute lymphoblastic leukemia (ALL) treatment. Beyond the development of chemotherapy regimens, immunotherapy is starting a new era with unprecedented complete remission (CR) rate. Targeting B-lineage-specific surface markers such as...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Guoqing, Wang, Jiasheng, Huang, He, Zhao, Yanmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563021/
https://www.ncbi.nlm.nih.gov/pubmed/28821272
http://dx.doi.org/10.1186/s13045-017-0516-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5563021/
https://www.ncbi.nlm.nih.gov/pubmed/28821272
http://dx.doi.org/10.1186/s13045-017-0516-x

Ejemplares similares